A pharmacoeconomic analysis of rimexolone for the treatment of ophthalmic inflammatory conditions

Michael Halpern, Cynthia S. Palmer, C. Stephen Foster, Ashish Pal, Carmelina Battista

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Topical steroids are the standard first-line therapy for treating ophthalmic inflammatory conditions. However, potent ophthalmic steroids can lead to an elevation of intraocular pressure (IOP), which can result in greater medical resource utilization and increased costs. We have developed a decision analysis model from a societal perspective to evaluate the costs and consequences of the treatment of ophthalmic inflammatory conditions with two potent topical steroids: prednisolone and rimexolone. Data for the model are based on information from clinical trials, national databases, published literature, and responses by ophthalmologists to a questionnaire on treatment patterns for elevated IOP. Three steroid-responsive conditions are examined separately with the model: uveitis; postoperative inflammation following cataract surgery; and other ophthalmic inflammatory conditions (blepharitis, episcleritis, postoperative refractive surgery, and corneal transplant). The model evaluates patients with acute conditions versus those with chronic conditions and those with mild to moderate elevation of IOP versus those with severe elevation of IOP. Although the unit cost of rimexolone is higher than that of prednisolone, use of rimexolone leads to cost savings because the incidence of elevated lOP is decreased. If rimexolone is used instead of prednisolone for the treatment of ophthalmic inflammatory conditions, the estimated cost saved (at 1995 AWP prices) is approximately $10 million across the entire US population. The savings across the health maintenance organization population on an annualized basis is approximately $3.9 million. Even if rimexolone were priced higher than current market charges (at 130% to 150% of the AWP of prednisolone), cost savings ranging from $2.9 million to $720,000 would accrue with use of rimexolone compared with prednisolone. However, if rimexolone were priced at 160% of the AWP of prednisolone, its use would incur an additional cost of $300,000. The primary medical resource utilized in treating elevated lOP in ophthalmic inflammatory conditions is physician visits. Medications are responsible for only one-fifth to one- third of the total cost of treating elevated IOP. This analysis indicates that rimexolone is associated with decreased medical resource utilization and cost savings to the entire healthcare system.

Original languageEnglish (US)
Pages (from-to)854-862
Number of pages9
JournalAmerican Journal of Managed Care
Volume4
Issue number6 SUPPL.
StatePublished - 1998
Externally publishedYes

Fingerprint

Pharmaceutical Economics
Prednisolone
Intraocular Pressure
costs
Cost Savings
Costs and Cost Analysis
savings
Steroids
Therapeutics
surgery
Blepharitis
Scleritis
utilization
Refractive Surgical Procedures
resources
Decision Support Techniques
Health Maintenance Organizations
rimexolone
Uveitis
model analysis

ASJC Scopus subject areas

  • Nursing(all)
  • Medicine(all)
  • Health(social science)
  • Health Professions(all)

Cite this

Halpern, M., Palmer, C. S., Stephen Foster, C., Pal, A., & Battista, C. (1998). A pharmacoeconomic analysis of rimexolone for the treatment of ophthalmic inflammatory conditions. American Journal of Managed Care, 4(6 SUPPL.), 854-862.

A pharmacoeconomic analysis of rimexolone for the treatment of ophthalmic inflammatory conditions. / Halpern, Michael; Palmer, Cynthia S.; Stephen Foster, C.; Pal, Ashish; Battista, Carmelina.

In: American Journal of Managed Care, Vol. 4, No. 6 SUPPL., 1998, p. 854-862.

Research output: Contribution to journalArticle

Halpern, M, Palmer, CS, Stephen Foster, C, Pal, A & Battista, C 1998, 'A pharmacoeconomic analysis of rimexolone for the treatment of ophthalmic inflammatory conditions', American Journal of Managed Care, vol. 4, no. 6 SUPPL., pp. 854-862.
Halpern, Michael ; Palmer, Cynthia S. ; Stephen Foster, C. ; Pal, Ashish ; Battista, Carmelina. / A pharmacoeconomic analysis of rimexolone for the treatment of ophthalmic inflammatory conditions. In: American Journal of Managed Care. 1998 ; Vol. 4, No. 6 SUPPL. pp. 854-862.
@article{8569bb5a86584dccb493f86fcd826d2c,
title = "A pharmacoeconomic analysis of rimexolone for the treatment of ophthalmic inflammatory conditions",
abstract = "Topical steroids are the standard first-line therapy for treating ophthalmic inflammatory conditions. However, potent ophthalmic steroids can lead to an elevation of intraocular pressure (IOP), which can result in greater medical resource utilization and increased costs. We have developed a decision analysis model from a societal perspective to evaluate the costs and consequences of the treatment of ophthalmic inflammatory conditions with two potent topical steroids: prednisolone and rimexolone. Data for the model are based on information from clinical trials, national databases, published literature, and responses by ophthalmologists to a questionnaire on treatment patterns for elevated IOP. Three steroid-responsive conditions are examined separately with the model: uveitis; postoperative inflammation following cataract surgery; and other ophthalmic inflammatory conditions (blepharitis, episcleritis, postoperative refractive surgery, and corneal transplant). The model evaluates patients with acute conditions versus those with chronic conditions and those with mild to moderate elevation of IOP versus those with severe elevation of IOP. Although the unit cost of rimexolone is higher than that of prednisolone, use of rimexolone leads to cost savings because the incidence of elevated lOP is decreased. If rimexolone is used instead of prednisolone for the treatment of ophthalmic inflammatory conditions, the estimated cost saved (at 1995 AWP prices) is approximately $10 million across the entire US population. The savings across the health maintenance organization population on an annualized basis is approximately $3.9 million. Even if rimexolone were priced higher than current market charges (at 130{\%} to 150{\%} of the AWP of prednisolone), cost savings ranging from $2.9 million to $720,000 would accrue with use of rimexolone compared with prednisolone. However, if rimexolone were priced at 160{\%} of the AWP of prednisolone, its use would incur an additional cost of $300,000. The primary medical resource utilized in treating elevated lOP in ophthalmic inflammatory conditions is physician visits. Medications are responsible for only one-fifth to one- third of the total cost of treating elevated IOP. This analysis indicates that rimexolone is associated with decreased medical resource utilization and cost savings to the entire healthcare system.",
author = "Michael Halpern and Palmer, {Cynthia S.} and {Stephen Foster}, C. and Ashish Pal and Carmelina Battista",
year = "1998",
language = "English (US)",
volume = "4",
pages = "854--862",
journal = "American Journal of Managed Care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "6 SUPPL.",

}

TY - JOUR

T1 - A pharmacoeconomic analysis of rimexolone for the treatment of ophthalmic inflammatory conditions

AU - Halpern, Michael

AU - Palmer, Cynthia S.

AU - Stephen Foster, C.

AU - Pal, Ashish

AU - Battista, Carmelina

PY - 1998

Y1 - 1998

N2 - Topical steroids are the standard first-line therapy for treating ophthalmic inflammatory conditions. However, potent ophthalmic steroids can lead to an elevation of intraocular pressure (IOP), which can result in greater medical resource utilization and increased costs. We have developed a decision analysis model from a societal perspective to evaluate the costs and consequences of the treatment of ophthalmic inflammatory conditions with two potent topical steroids: prednisolone and rimexolone. Data for the model are based on information from clinical trials, national databases, published literature, and responses by ophthalmologists to a questionnaire on treatment patterns for elevated IOP. Three steroid-responsive conditions are examined separately with the model: uveitis; postoperative inflammation following cataract surgery; and other ophthalmic inflammatory conditions (blepharitis, episcleritis, postoperative refractive surgery, and corneal transplant). The model evaluates patients with acute conditions versus those with chronic conditions and those with mild to moderate elevation of IOP versus those with severe elevation of IOP. Although the unit cost of rimexolone is higher than that of prednisolone, use of rimexolone leads to cost savings because the incidence of elevated lOP is decreased. If rimexolone is used instead of prednisolone for the treatment of ophthalmic inflammatory conditions, the estimated cost saved (at 1995 AWP prices) is approximately $10 million across the entire US population. The savings across the health maintenance organization population on an annualized basis is approximately $3.9 million. Even if rimexolone were priced higher than current market charges (at 130% to 150% of the AWP of prednisolone), cost savings ranging from $2.9 million to $720,000 would accrue with use of rimexolone compared with prednisolone. However, if rimexolone were priced at 160% of the AWP of prednisolone, its use would incur an additional cost of $300,000. The primary medical resource utilized in treating elevated lOP in ophthalmic inflammatory conditions is physician visits. Medications are responsible for only one-fifth to one- third of the total cost of treating elevated IOP. This analysis indicates that rimexolone is associated with decreased medical resource utilization and cost savings to the entire healthcare system.

AB - Topical steroids are the standard first-line therapy for treating ophthalmic inflammatory conditions. However, potent ophthalmic steroids can lead to an elevation of intraocular pressure (IOP), which can result in greater medical resource utilization and increased costs. We have developed a decision analysis model from a societal perspective to evaluate the costs and consequences of the treatment of ophthalmic inflammatory conditions with two potent topical steroids: prednisolone and rimexolone. Data for the model are based on information from clinical trials, national databases, published literature, and responses by ophthalmologists to a questionnaire on treatment patterns for elevated IOP. Three steroid-responsive conditions are examined separately with the model: uveitis; postoperative inflammation following cataract surgery; and other ophthalmic inflammatory conditions (blepharitis, episcleritis, postoperative refractive surgery, and corneal transplant). The model evaluates patients with acute conditions versus those with chronic conditions and those with mild to moderate elevation of IOP versus those with severe elevation of IOP. Although the unit cost of rimexolone is higher than that of prednisolone, use of rimexolone leads to cost savings because the incidence of elevated lOP is decreased. If rimexolone is used instead of prednisolone for the treatment of ophthalmic inflammatory conditions, the estimated cost saved (at 1995 AWP prices) is approximately $10 million across the entire US population. The savings across the health maintenance organization population on an annualized basis is approximately $3.9 million. Even if rimexolone were priced higher than current market charges (at 130% to 150% of the AWP of prednisolone), cost savings ranging from $2.9 million to $720,000 would accrue with use of rimexolone compared with prednisolone. However, if rimexolone were priced at 160% of the AWP of prednisolone, its use would incur an additional cost of $300,000. The primary medical resource utilized in treating elevated lOP in ophthalmic inflammatory conditions is physician visits. Medications are responsible for only one-fifth to one- third of the total cost of treating elevated IOP. This analysis indicates that rimexolone is associated with decreased medical resource utilization and cost savings to the entire healthcare system.

UR - http://www.scopus.com/inward/record.url?scp=0031904423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031904423&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 854

EP - 862

JO - American Journal of Managed Care

JF - American Journal of Managed Care

SN - 1088-0224

IS - 6 SUPPL.

ER -